Martyna Wyszyńska-Gołaszewska, Wojciech Naumnik

1st Department of Lung Diseases, Lung Cancer and Internal Diseases, Medical University of Bialystok, Bialystok, Poland

Factors influencing the prognosis of COVID-19 patients treated with High--Flow Nasal Oxygen Therapy (HFNOT) — a retrospective analysis

Corresponding author:

Martyna Wyszyńska-Gołaszewska, MD
1st Department of Lung Diseases,
 Lung Cancer and Internal Diseases,
Medical University of Bialystok,
Żurawia 14 St., 15–540 Białystok
tel.: (85) 8316524
e-mail:
lek.martyna.wyszynskagolaszewska@
gmail.com

ABSTRACT

Introduction: HFNOT plays an essential role in the management of respiratory failure in COVID-19 patients. However, identifying precise prognostic factors to predict HFNOT outcomes remains crucial for optimizing patient management.

Material and methods: A retrospective analysis was made of 103 patients treated with HFNOT in Temporary Hospital nr 1 in Białystok. HFNOT failure group (58 pts; 56.3%) was defined as patients requiring treatment escalation, intubated, and/or patients who died. The rest was the success group (45 pts; 43.7%). Clinical factors and laboratory tests were analyzed at the beginning of HFNOT, after 2, 24, and 72 hours after the start of treatment, and at the end of treatment. Statistical analysis was run in R software, version R4.1.2.

Results: It was found that age, arterial hypertension, heart failure, HFNOT duration days and levels of C-reactive protein, procalcitonin, number of white blood cells close to termination of the therapy, the oxygen content of the respiratory mixture (%) in 24h, heart rate in 72h, partial pressure of oxygen (mmHg) at the beginning of therapy and saturation during treatment are prognostic factors allowing to predict the effect of HFNOT therapy ($p < 0.05$). The use of convalescent plasma, remdesivir, tocylizumab, and olumiant has not been shown to improve the impact of the HFNOT used.

Conclusions: This study highlights critical prognostic factors that influence the outcomes of COVID-19 patients treated with HFNOT. Further research is needed to refine these prognostic models and to explore the potential of early invasive ventilation in patients with unfavorable prognostic indicators.

Keywords: COVID-19, HFNOT (high-flow nasal oxygen therapy), prognosis of COVID-19 patients

Med Res J 2024; 9 (4): 371–378

Introduction

High-Flow Nasal Oxygen Therapy (HFNOT) is recommended by the National Institutes of Health (NIH) and the Surviving Sepsis Campaign guidelines for the treatment of acute hypoxemic respiratory failure during COVID-19, requiring support beyond conventional oxygen devices [1, 2]. HFNOT is a safe method of respiratory support in COVID-19 patients, reducing the need for invasive ventilation and therapy escalation compared to Conventional Oxygen Therapy (COT) in patients with COVID-19 and acute hypoxemic respiratory failure [3]. Additionally, it significantly reduces the number of intubations and subsequent invasive mechanical ventilation [4]. However, no specific defined factors affect the prognosis of patients treated with this method.

The main objective of this analysis was to determine the factors influencing the prognosis of patients with COVID-19 treated with high-flow nasal oxygen therapy.

Material and methods

A retrospective analysis was made of 103 patients treated with HFNOT in Temporary Hospital nr 1 in Białystok from December 2020 to April 2022. Clinical factors

and laboratory tests were analyzed at the beginning of HFNOT, after 2, 24, and 72 hours after the start of treatment, and at the end of treatment. The criterion for initiating high-flow oxygen therapy was $SpO_2 \leq 92\%$ and/or $RR \geq 25$ times/min while using conventional oxygen therapy. In most patients, the HFNOT flow was 30–60 L/min, FiO_2 100% to maintain oxygen saturation at 92–96%. HFNOT failure group (58 pts; 56.3%) was defined as patients requiring treatment escalation, intubated, and/or patients who died. The rest was the success group (45 pts; 43.7%). Patients undergoing high-flow oxygen therapy received treatment by applicable standards for the treatment of COVID-19 infection with respiratory failure.

Statistical analysis was run in R software, version R4.1.2. Groups were compared with the t-student independent test, Mann–Whitney U-test, Pearson chi-square test, or Fisher exact test, as appropriate. Two-step logistic regression was used to quantify the impact of selected predictors on the odds of therapy failure. All tests assumed statistical significance when $p < 0.05$.

Results

Characteristics of all patients and their comparison between failure and success groups

The study group consisted of 103 patients aged 68.83 ± 15.00 years on average treated with HFNOT in Temporary Hospital nr 1 in Białystok, out of which 45.6% were female. Over half of the patients suffered from arterial hypertension (AH), one-third were obese, and roughly one out of five had atrial fibrillation (AF), heart failure (HF), or type 2 diabetes mellitus (T2DM). HFNOT lasted typically 6.00 days. Patients were treated with remdesivir or tocylizumab, less frequently with olumiant or plasma. Over one-third of patients were intubated, and a similar proportion of patients died. Detailed basic characteristics are presented in Table 1.

HFNOT failure group was defined as patients requiring treatment escalation, intubated, and/or patients who died. It consisted of n = 58 patients (56.3%). The rest was defined as a success group (n = 45, 43.7%). The average age was significantly higher in the failure group. The failure group suffered from AH and HF significantly more often compared to the success group. The proportion of patients with AH in the failure group was 75.9% and in the success group, it was 53.3%. The proportion of patients with HF in the failure group was 32.8% while in the success group, n = 3 patients suffered from HF. HFNOT lasted three days in the failure group and 11.00 days in the success group, difference

Table 1. Basic characteristics in the total group

Variable	All patients (n = 103)
Sex, female [n (%)]	47 (45.6)
Age [years]	68.83 ± 15.00
Weight [kg]	90.24 ± 17.97
Height [m]	1.69 ± 0.09
BMI [kg/m^2]	31.67 ± 5.52
Comorbidities [n (%)]	
AH	68 (66.0)
T2DM	19 (18.4)
COPD/Asthma	8 (7.8)
CKD	6 (5.8)
Obesity	35 (34.0)
AF	23 (22.3)
HF	22 (21.4)
Mental illness	7 (6.8)
Active cancer	3 (2.9)
Other disease	42 (40.8)
HFNOT duration [days]	6.00 (2.00;11.00)
NIV [n (%)]	26 (35.6)
Drugs [n (%)]	
Remdesivir	26 (25.2)
Tocilizumab	24 (23.3)
Plasma	2 (1.9)
Olumiant	13 (12.6)
HRCT [points]	18.00 (13.25;20.00)
HRCT [%]	62.73 ± 19.86
Intubation [n (%)]	35 (34.0)
Death [n (%)]	27 (32.5)

BMI — body mass index; AH — arterial hypertension; T2DM — type 2 diabetes mellitus; COPD — chronic obstructive pulmonary disease; CKD — chronic kidney disease; AF — atrial fibrillation; HF — heart failure; HFNOT — high-flow nasal oxygen therapy; NIV — non-invasive ventilation;
HRCT — high resolution computed tomography. Data presented as n [%] for categorical parameters and mean ± standard deviation or median (interquartile range), depending on distribution normality, for numerical parameters

was statistically significant. Non-invasive ventilation (NIV) was added to the therapy in the case of half of the failure group (53.7%) (Table 2).

At the start of HFNOT patients who died and/or were intubated differed from the success group with procalcitonin (PCT) level, which was significantly higher in the failure group. At the end of the therapy patients with failed outcomes had significantly higher levels of C-reactive protein (CRP), PCT, D-dimer, ferritin, white blood cells (WBC), aspartate transaminase (AST), creatinine and interleukin-6 (IL-6) compared to patients with positive outcome of the therapy (Table 3).

Table 2. Basic characteristics — comparison between failure and success groups

Variable	HFNOT failure (n = 58)	HFNOT success (n = 45)	MD (95% CI)	p
Sex, female [n (%)]	29 (50.0)	18 (40.0)	–	0.417
Age [years]	72.71 ± 15.16	63.82 ± 13.37	8.88 (3.21; 14.56)	0.002[1]
Weight [kg]	88.75 ± 16.85	91.95 ± 19.45	–3.20 (–14.11; 7.71)	0.557[1]
Height [m]	1.68 ± 0.09	1.70 ± 0.09	–0.01 (–0.07; 0.04)	0.627[1]
BMI [kg/m^2]	31.74 ± 5.23	31.60 ± 5.96	0.14 (–3.04; 3.32)	0.930[1]
Comorbidities [n (%)]				
AH	44 (75.9)	24 (53.3)	–	0.029
T2DM	13 (22.4)	6 (13.3)	–	0.356
COPD/Asthma	4 (6.9)	4 (8.9)	–	0.727[2]
CKD	5 (8.6)	1 (2.2)	–	0.228[2]
Obesity	20 (34.5)	15 (33.3)	–	> 0.999
AF	15 (25.9)	8 (17.8)	–	0.460
HF	19 (32.8)	3 (6.7)	–	0.003
Mental illness	4 (6.9)	3 (6.7)	–	> 0.999[2]
Active cancer	3 (5.2)	0 (0.0)	–	0.255[2]
Other disease	23 (39.7)	19 (42.2)	–	0.951
HFNOT duration days	3.00 (2.00; 5.00)	11.00 (7.00;16.00)	–8.00 (–10.00; –6.00)	< 0.001
NIV [n (%)]	22 (53.7)	4 (12.5)	–	0.001
Drugs [n (%)]				
Remdesivir	15 (25.9)	11 (24.4)	–	> 0.999
Tocylizumab	12 (20.7)	12 (26.7)	–	0.634
Plasma	1 (1.7)	1 (2.2)	–	> 0.999[2]
Olumiant	5 (8.6)	8 (17.8)	–	0.276
HRCT [points]	19.00 (14.75; 21.00)	17.00 (12.00; 20.00)	2.00 (–1.00; 4.00)	0.272
HRCT [%]	66.25 ± 19.20	58.50 ± 20.82	7.75 (–10.07; 25.57)	0.375[1]

MD — mean or median difference (failure vs success); CI — confidence interval; BMI — body mass index; AH — arterial hypertension; T2DM — type 2 diabetes mellitus; COPD — chronic obstructive pulmonary disease; CKD — chronic kidney disease; AF — atrial fibrillation; HF — heart failure; HFNOT — high-flow nasal oxygen therapy; NIV — non-invasive ventilation; HRCT — high resolution computed tomography. Data presented as n [%] for categorical parameters and mean ± standard deviation or median (interquartile range), depending on distribution normality, for numerical parameters. Failure is defined as death and/or intubation. Success is defined as not intubated and not dead

Failure and success groups were significantly differentiated with FiO_2 levels after 24h and 72h, respectively. Also, HR and PO_2/FiO_2 differed between the groups after 72h. HR was higher within the failure group. PO_2/FiO_2 was lower in patients who failed the therapy. Ph after 24h was significantly lower within the failure group. PO_2 at the therapy start had a significantly lower level in the failure group. Saturation was significantly lower in the failure group at every record (Table 4).

Logistic regression analysis — parameters determining the odds of therapy failure

Two-step logistic regression was performed to identify factors impacting the odds of HFNOT failure.

In the univariate step, it was found that age impacts the odds significantly. In the case of patients one year older, the chance of therapy failure was 4% higher. AH and HF would increase the odds of failure almost 3× and 7×, respectively.

One more day of therapy duration was associated with 22% lower odds of failure. Using NIV was associated with 8× higher odds of failure. CRP, PCT, and WBC close to termination of the therapy determined its outcome in a significant way. CRP and WBC higher by one resulted in 7% and 17% higher failure odds, respectively. PCT effect size was substantial when the factor was higher by one unit. Additionally, substantially increased odds of therapy failure were observed with FiO_2 24h increase by one unit.

Table 3. Laboratory tests outcomes in split-to-failure and success groups

Variable	HFNOT failure (n = 58)	HFNOT success (n = 45)	MD (95% CI)	p
At HFNOT start				
CRP	114.50 (83.86; 191.25)	131.00 (84.00; 205.00)	–16.50 (–45.00; 16.00)	0.382
PCT	0.22 (0.09; 0.72)	0.09 (0.05; 0.27)	0.14 (0.00; 0.17)	0.009
D–dimer	1283.00 (680.50; 1796.50)	1086.00 (737.00; 2160.00)	197.00 (–271.00; 408.00)	0.668
Ferritin	1356.00 (817.00; 2850.00)	1135.50 (778.50; 1588.00)	220.50 (–122.00; 706.00)	0.193
WBC	7.06 (5.23; 9.29)	6.40 (4.67; 8.62)	0.66 (–0.45; 1.97)	0.230
RBC	4.27 ± 0.66	4.49 ± 0.60	–0.22 (–0.47; 0.03)	0.083[1]
HGB	12.94 ± 1.85	13.52 ± 1.75	–0.58 (–1.30; 0.14)	0.110[1]
PLT	192.55 ± 81.50	189.22 ± 83.03	3.33 (–29.32; 35.97)	0.840[1]
AST	61.50 (44.00; 83.00)	55.00 (40.00; 83.00)	6.50 (–6.00; 18.00)	0.270
ALT	38.50 (26.25; 57.50)	36.00 (24.00; 54.00)	2.50 (–5.00; 12.00)	0.476
Creatinine	1.04 (0.84; 1.35)	0.91 (0.77; 1.08)	0.13 (–0.03; 0.27)	0.122
IL-6	94.50 (59.25; 169.25)	86.00 (55.80; 167.00)	8.50 (–27.00; 36.80)	0.676
HFNOT termination				
CRP	77.73 (38.00; 150.00)	2.67 (0.97; 5.09)	75.06 (62.01; 101.09)	< 0.001
PCT	0.35 (0.10; 2.67)	0.05 (0.05; 0.07)	0.30 (0.20; 0.84)	< 0.001
D–dimer	3149.00 (1347.50; 6054.50)	841.00 (511.50; 1919.50)	2308.00 (750.00; 3197.00)	< 0.001
Ferritin	1512.00 (917.50; 3612.50)	665.00 (516.00; 916.00)	847.00 (121.00; 2386.00)	0.015
WBC	11.22 (8.93; 15.60)	8.16 (5.94; 11.44)	3.06 (1.31; 4.88)	0.001
RBC	4.23 ± 0.71	4.21 ± 0.55	0.01 (–0.25; 0.27)	0.928[1]
HGB	12.87 ± 2.02	12.76 ± 1.61	0.10 (–0.65; 0.86)	0.786[1]
PLT	232.62 ± 82.44	226.47 ± 87.62	6.15 (–29.07; 41.37)	0.729[1]
AST	40.00 (30.75; 60.00)	26.00 (21.00; 38.00)	14.00 (6.00; 20.00)	< 0.001
ALT	38.50 (29.75; 53.50)	46.00 (28.00; 72.00)	–7.50 (–17.00; 4.00)	0.263
Creatinine	0.93 (0.71; 1.31)	0.79 (0.60; 0.93)	0.14 (0.04; 0.33)	0.013
IL-6	51.50 (31.05; 138.00)	8.40 (2.60; 57.50)	43.10 (16.70; 58.80)	< 0.001

MD — mean or median difference (failure vs success); CI — confidence interval; HFNOT — high-flow nasal oxygen therapy; CRP — C-reactive protein, PCT — procalcitonin, WBC — white blood cells; RBC — red blood cells; HGB — haemoglobin; PLT — blood platelets; AST — aspartate transaminase; ALT — alanine transaminase; IL-6 — interleukin-6. Data presented as mean ± standard deviation or median (interquartile range), depending on distribution normality. Failure is defined as death and/or intubation. Success is defined as not intubated and not dead. Comparisons made with t-Student independent test[1] or Mann–Whitney U test, as appropriate

Higher HR 72h was associated with increased odds of failure. The partial pressure of oxygen (mmHg) at the beginning of therapy higher by one decreased the odds by 27%. Saturation higher by one percentage point meant decreased odds of failure by 10–20%, depending on the timing of measurement (Table 5).

In the multivariate analysis, the odds of therapy failure were dependent on saturation at 24h and 72h, HR at 72h, and HF disease. Saturation after 24h higher by one percentage point was associated with 51% higher odds of failure. Saturation after 72h higher by one percentage point was associated with 20% lower odds of failure. HR after 72h higher by one resulted in 9% higher odds

of failure. HF disease resulted in 14× increased odds of failure. Other predictors included in the multivariate model (saturation after 2h, AH disease, and FiO_2 after 24h) did not prove to impact failure odds significantly.

Discussion

The application of High-Flow Nasal Oxygen Therapy in managing acute hypoxemic respiratory failure, particularly among COVID-19 patients, has revolutionized treatment protocols by minimizing the necessity for invasive mechanical ventilation (IMV) [5, 6].

Table 4. Respiratory and cardiological parameters over time in split into failure and success groups

Variable	Time [h]	HFNOT failure (n = 58)	HFNOT success (n = 45)	MD (95% CI)	p
sBP	0	131.04 ± 19.84	132.00 ± 22.17	–0.96 (–9.47; 7.55)	0.823[1]
	2	136.23 ± 21.71	130.48 ± 15.46	5.74 (–3.43; 14.92)	0.216[1]
	24	130.16 ± 20.36	125.73 ± 21.97	4.43 (–4.20; 13.05)	0.311[1]
	72	130.66 ± 20.18	124.49 ± 19.61	6.17 (–3.34; 15.68)	0.200[1]
	Int.	–	–	–	–
dBP	0	75.75 ± 13.60	78.89 ± 13.48	–3.14 (–8.64; 2.36)	0.259[1]
	2	76.71 ± 9.81	75.39 ± 10.61	1.32 (–3.63; 6.27)	0.596[1]
	24	75.80 ± 11.85	75.53 ± 13.43	0.27 (–4.88; 5.42)	0.918[1]
	72	77.00 (70.00; 86.00)	76.00 (67.50; 81.50)	1.00 (–4.00; 9.00)	0.425
	Int.	–	–	–	–
FiO_2	0	0.80 (0.21; 0.80)	0.80 (0.80; 0.80)	0.00 (0.00; 0.00)	0.390
	2	1.00 (1.00; 1.00)	1.00 (1.00; 1.00)	0.00 (0.00; 0.00)	0.467
	24	1.00 (1.00; 1.00)	1.00 (0.90; 1.00)	0.00 (0.00; 0.00)	0.026
	72	1.00 (1.00; 1.00)	1.00 (0.90; 1.00)	0.00 (0.00; 0.00)	0.045
	Int.	–	–	–	–
HCO_3	0	22.35 ± 4.47	22.39 ± 2.62	–0.05 (–3.01; 2.92)	0.975[1]
	2	22.97 ± 4.44	23.82 ± 3.34	–0.85 (–3.80; 2.11)	0.565[1]
	24	23.42 ± 3.71	24.31 ± 3.75	–0.90 (–3.24; 1.45)	0.445[1]
	72	24.71 ± 3.92	25.15 ± 3.42	–0.43 (–3.31; 2.45)	0.760[1]
	Int.	–	–	–	–
HR	0	90.00 (79.50; 100.00)	88.00 (75.00; 100.00)	2.00 (–5.00; 10.00)	0.633
	2	83.14 ± 14.54	78.30 ± 13.70	4.84 (–2.01; 11.69)	0.163[1]
	24	84.52 ± 17.45	79.31 ± 15.52	5.21 (–1.55; 11.97)	0.129[1]
	72	87.45 ± 13.69	76.52 ± 12.90	10.92 (4.56; 17.29)	0.001[1]
	Int.	–	–	–	–
Lac	0	2.79 ± 1.37	2.17 ± 0.76	0.62 (–0.77; 2.01)	0.348[1]
	2	2.05 (1.67; 2.72)	1.70 (1.45; 2.05)	0.35 (–0.30; 1.10)	0.315
	24	2.38 ± 1.28	1.98 ± 0.49	0.40 (–0.56; 1.37)	0.398[1]
	72	2.43 ± 0.95	2.60 ± 0.93	–0.17 (–1.31; 0.98)	0.757[1]
	Int.	1.90 (1.85; 2.55)	–	–	–
PO_2/FiO_2	0	64.75 (56.28; 135.78)	68.75 (65.12; 71.25)	–4.00 (–15.96; 6.50)	0.254
	2	64.60 (59.75; 74.90)	89.60 (70.60; 105.80)	–25.00 (–37.49; 0.10)	0.060
	24	62.56 (49.90; 73.90)	68.22 (59.55; 84.30)	–5.67 (–18.44; 5.70)	0.310
	72	58.50 (50.90; 72.00)	73.30 (62.20; 116.90)	–14.80 (–36.70; –0.60)	0.040
	Int.	–	–	–	–
pCO_2	0	32.05 (30.35; 35.03)	35.35 (29.35; 39.22)	–3.30 (–7.30; 3.30)	0.435
	2	31.98 ± 5.08	33.95 ± 6.08	–1.96 (–5.63; 1.70)	0.285[1]
	24	35.33 ± 5.31	34.61 ± 7.82	0.72 (–3.09; 4.53)	0.705[1]
	72	34.00 (30.80; 36.20)	36.95 (31.15; 40.78)	–2.95 (–6.40; 3.10)	0.634
	Int.	–	–	–	–
ph	0	7.43 ± 0.03	7.43 ± 0.07	0.00 (–0.04; 0.04)	0.983[1]
	2	7.45 ± 0.04	7.45 ± 0.04	0.00 (–0.02; 0.03)	0.793[1]

→

Table 4 cont. Respiratory and cardiological parameters over time in split into failure and success groups

	24	7.42 ± 0.04	7.46 ± 0.05	−0.03 (−0.06; −0.01)	0.013[1]
	72	7.43 (7.41; 7.48)	7.45 (7.41; 7.49)	−0.02 (−0.06; 0.03)	0.474
	Int.	7.43 (7.40; 7.47)	−	−	−
PO_2	0	45.30 (41.12; 49.55)	54.50 (52.10; 56.35)	−9.20 (−15.00; −4.00)	0.001[1]
	2	64.60 (58.15; 74.90)	72.60 (67.30; 105.80)	−8.00 (−32.80; 2.00)	0.091
	24	60.50 (49.90; 73.90)	65.30 (55.55; 76.40)	−4.80 (−14.40; 8.10)	0.582
	72	58.50 (50.80; 72.00)	71.50 (62.20; 116.90)	−13.00 (−34.50; 1.80)	0.094
	Int.	−	−	−	−
Sat.	0	83.00 (74.25; 86.00)	88.00 (83.00; 89.00)	−5.00 (−7.80; −2.00)	< 0.001
	2	93.00 (91.15; 95.15)	95.00 (93.80; 96.20)	−2.00 (−3.00; −0.40)	0.009
	24	92.25 (86.70; 95.00)	95.00 (92.00; 96.00)	−2.75 (−4.00; −1.00)	0.005
	72	88.90 (82.00; 92.80)	96.00 (94.00; 98.00)	−7.10 (−10.10; −4.00)	< 0.001
	Int.	88.20 (83.60; 90.00)	−	−	−

HFNOT — high-flow nasal oxygen therapy; MD — mean or median difference (failure *vs.* success); CI — confidence interval; sBP — systolic blood pressure; dBP — diastolic blood pressure; FiO_2 — fraction of inspired oxygen; HCO_3 — bicarbonate concentration; Lac — lactate; PO_2/FiO_2 — ratio of arterial oxygen partial pressure to fractional inspired oxygen; pCO_2 — partial pressure of carbon dioxide; ph — ph value; PO_2 — partial pressure of oxygen; Sat. — saturation; Int. — intubation. Data presented as mean ± standard deviation or median (interquartile range), depending on distribution normality. Failure is defined as death and/or intubation. Success is defined as not intubated and not dead. Comparisons made with t-Student independent test[1] or Mann–Whitney U test, as appropriate

However, identifying precise prognostic factors to predict HFNOT outcomes remains crucial for optimizing patient management.

Our findings indicate that age is a significant prognostic factor for HFNOT outcomes. Advanced age is well-documented as a predictor of poor prognosis in COVID-19 patients due to a higher incidence of comorbidities and diminished physiological reserve. In the present study, each additional year of age increased the odds of HFNOT failure by 4%. This is consistent with studies showing that older adults are particularly vulnerable to severe outcomes in COVID-19, especially when requiring respiratory support [7]. A study by Grasselli et al. [8] corroborates this, demonstrating that advanced age is a critical determinant of mortality among COVID-19 patients in intensive care units.

Cardiovascular comorbidities, such as arterial hypertension and heart failure, were also found to be significant predictors of HFNOT failure in the present analysis. Patients with AH had nearly a threefold increased risk of therapy failure, while those with HF faced a sevenfold increase in risk. In the present study, in the case of patients treated with HFNOT, heart failure increased the odds of therapy failure almost 7 times. These findings are supported by existing literature, which indicates that patients with pre-existing cardiovascular conditions have a higher susceptibility to severe COVID-19 complications and poorer outcomes when subjected to non-invasive respiratory support [9–11]. For instance, Chatrath et al. [12] highlighted the poor prognosis for COVID-19 patients with concomitant heart failure, underlining the challenges in managing these high-risk patients.

Our study also identified the duration of HFNOT as a critical factor in patient outcomes. Patients in the failure group required therapy escalation within three days, compared to eleven days in the success group. This finding aligns with recent evidence suggesting that prolonged non-invasive support, without timely escalation to IMV, may lead to worse outcomes, particularly in patients with lower initial PaO_2 values [13, 14]. The systematic review by Ridjab et al. [15] supports early intubation in severe cases of COVID-19-associated ARDS to mitigate the risks associated with delayed invasive ventilation. In the present analysis, NIV was added to the therapy in case of increasing respiratory effort and decreasing saturation in patients treated with HFNOT. Half of the failure group was treated with non-invasive ventilation (53,7%). Necessity of NIV application was associated with 8 times higher odds of failure. It is possible that the older age of the patients and comorbidities worsened the prognosis and also contributed to the failure of NIV.

In the present study, inflammatory markers, including C-reactive protein (CRP), procalcitonin (PCT), and white blood cell (WBC) count, were significantly elevated at the termination of HFNOT in the failure group, suggesting a link between these markers and poor outcomes. The present studies corroborate the findings reported by other authors [16, 17].

Table 5. Logistic regression outcomes for failure of HFNOT. The table presents statistically significant results from the univariate model. For the remaining variables, the regression results were not significant

Variable	Univariate model		
	OR	95% CI	p
Age [years]	1.04	1.01–1.08	0.004
Comorbidities [n (%)]			
AH	2.75	1.20–6.48	0.018
HF	6.82	2.12–30.65	0.004
HFNOT duration days	0.78	0.70–0.86	< 0.001
NIV [n (%)]	8.11	2.61–31.16	< 0.001
CRP at HFNOT termination	1.07	1.04–1.11	< 0.001
PCT at HFNOT termination	114; 126.80	379.97–Inf	< 0.001
WBC at HFNOT termination	1.17	1.06–1.32	0.004
FiO$_2$			
0	0.46	0.08–2.29	0.348
2	93.20	0.11–289; 053.23	0.209
24	38693.17	12.62–Inf	0.025
72	544; 726.88	3.75–Inf	0.087
HR			
0	1.00	0.98–1.02	0.876
2	1.03	0.99–1.06	0.163
24	1.02	0.99–1.05	0.132
72	1.06	1.02–1.11	0.002
PO$_2$			
0	0.73	0.54–0.88	0.009
2	0.98	0.95–1.01	0.124
24	1.00	0.98–1.03	0.852
72	0.98	0.96–1	0.140
Sat.			
0	0.90	0.84–0.95	0.001
2	0.82	0.69–0.95	0.014
24	0.88	0.79–0.96	0.009
72	0.80	0.70–0.88	< 0.001

OR — odds ratio; CI — confidence interval; Sat. — saturation; HFNOT — high-flow nasal oxygen therapy; NIV — non-invasive ventilation; CRP — C-reactive protein; PCT — procalcitonin; WBC — white blood cells; HR — heart rate. Failure is defined as death and/or intubation

Elevated levels of these markers may indicate secondary bacterial infections, a common complication in critically ill COVID-19 patients, which are known to worsen prognosis [16, 17]. Liu et al. [18] have demonstrated that high levels of CRP and PCT are associated with severe disease and poor outcomes in COVID-19 patients, reinforcing the importance of monitoring these biomarkers during HFNOT.

Interestingly, the use of adjunctive therapies such as remdesivir, tocilizumab, and convalescent plasma did not significantly improve HFNOT outcomes in the present cohort. This finding is consistent with recent meta-analyses that have questioned the effectiveness of these treatments in altering the course of severe COVID-19, particularly when used alongside advanced respiratory support [19]. A study by Pilgram et al. [20] also concluded that remdesivir did not significantly impact the outcomes of severe COVID-19 cases, suggesting that its role may be limited in the context of advanced respiratory interventions.

One limitation of the present study was the inability to calculate the ROX index due to the absence of respiratory rate data. The ROX index has been validated as a predictor of HFNOT success, and its inclusion could enhance the early identification of patients at risk for treatment failure [21]. The work by de Carvalho et al. [22] underscores the utility of the ROX index in predicting the need for mechanical ventilation in COVID-19 patients undergoing HFNOT.

Conclusions

In conclusion, this study highlights critical prognostic factors that influence the outcomes of COVID-19 patients treated with HFNOT. Age, cardiovascular comorbidities, duration of HFNOT, and inflammatory markers are pivotal in predicting therapy success or failure. These findings suggest that an integrated approach, combining close monitoring of clinical parameters with timely therapeutic interventions, is essential for optimizing outcomes in this patient population. Further research is needed to refine these prognostic models and to explore the potential of early invasive ventilation in patients with unfavorable prognostic indicators.

Article information

References

1. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health; 2021. https://www.covid19treatmentguidelines.nih.gov/ (23.03.2021).

2. Alhazzani W, Møller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020; 46(5): 854–887, doi: 10.1007/s00134-020-06022-5, indexed in Pubmed: 32222812.

3. Agarwal A, Basmaji J, Muttalib F, et al. High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission. Can J Anaesth. 2020; 67(9): 1217–1248, doi: 10.1007/s12630-020-01740-2, indexed in Pubmed: 32542464.

4. Demoule A, Vieillard Baron A, Darmon M, et al. High-flow nasal cannula in critically III patients with severe COVID-19. Am J Respir Crit Care Med. 2020; 202(7): 1039–1042, doi: 10.1164/rccm.202005-2007LE, indexed in Pubmed: 32758000.

5. García-Pereña L, Ramos Sesma V, Tornero Divieso ML, et al. Benefits of early use of high-flow-nasal-cannula (HFNC) in patients with COVID-19 associated pneumonia. Med Clin (Engl Ed). 2022; 158(11): 540–542, doi: 10.1016/j.medcle.2021.05.024, indexed in Pubmed: 35634247.

6. Le Pape S, Savart S, Arrivé F, et al. High-flow nasal cannula oxygen versus conventional oxygen therapy for acute respiratory failure due to COVID-19: a systematic review and meta-analysis. Ann Intensive Care. 2023; 13(1): 114, doi: 10.1186/s13613-023-01208-8, indexed in Pubmed: 37994981.

7. Endeshaw Y, Campbell K. Advanced age, comorbidity and the risk of mortality in COVID-19 infection. J Natl Med Assoc. 2022; 114(5): 512––517, doi: 10.1016/j.jnma.2022.06.005, indexed in Pubmed: 35786506.

8. Grasselli G, Greco M, Zanella A, et al. COVID-19 Lombardy ICU Network. Risk factors associated with mortality among patients with COVID-19 in intensive care units in lombardy, Italy. JAMA Intern Med. 2020; 180(10): 1345–1355, doi: 10.1001/jamainternmed.2020.3539, indexed in Pubmed: 32667669.

9. Ata F, Montoro-Lopez MN, Awouda S, et al. COVID-19 and heart failure: the big challenge. Heart Views. 2020; 21(3): 187–192, doi: 10.4103/HEARTVIEWS.HEARTVIEWS_122_20, indexed in Pubmed: 33688410.

10. Yang J, Zheng Ya, Gou Xi, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020; 94: 91–95, doi: 10.1016/j.ijid.2020.03.017, indexed in Pubmed: 32173574.

11. Zhou Y, Yang Q, Chi J, et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. Int J Infect Dis. 2020; 99: 47–56, doi: 10.1016/j.ijid.2020.07.029, indexed in Pubmed: 32721533.

12. Chatrath N, Kaza N, Pabari PA, et al. The effect of concomitant COVID-19 infection on outcomes in patients hospitalized with heart failure. ESC Heart Fail. 2020; 7(6): 4443–4447, doi: 10.1002/ehf2.13059, indexed in Pubmed: 33040480.

13. Raboni SM, Neves VC, Silva RM, et al. High-flow nasal cannula therapy in patients with COVID-19: predictive response factors. Respir Care. 2022; 67(11): 1443–1451, doi: 10.4187/respcare.09764, indexed in Pubmed: 35944966.

14. Kasarabada A, Barker K, Ganoe T, et al. How long is too long: A retrospective study evaluating the impact of the duration of noninvasive oxygenation support strategies (high flow nasal cannula & BiPAP) on mortality in invasive mechanically ventilated patients with COVID-19. PLoS One. 2023; 18(2): e0281859, doi: 10.1371/journal.pone.0281859, indexed in Pubmed: 36795723.

15. Ridjab DA, Ivan I, Budiman F, et al. Outcome in early vs late intubation among COVID-19 patients with acute respiratory distress syndrome: an updated systematic review and meta-analysis. Sci Rep. 2022; 12(1): 21588, doi: 10.1038/s41598-022-26234-7, indexed in Pubmed: 36517555.

16. Chen T, Wu Di, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020; 368: m1091, doi: 10.1136/bmj.m1091, indexed in Pubmed: 32217556.

17. Cheng K, He M, Shu Q, et al. Analysis of the risk factors for nosocomial bacterial infection in patients with COVID-19 in a tertiary hospital. Risk Manag Healthc Policy. 2020; 13: 2593–2599, doi: 10.2147/RMHP.S277963, indexed in Pubmed: 33223859.

18. Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020; 127: 104370, doi: 10.1016/j.jcv.2020.104370, indexed in Pubmed: 32344321.

19. Cillóniz C, Motos A, Castañeda T, et al. CIBERESUCICOVID Project (COV20/00110, ISCIII). Remdesivir and survival outcomes in critically ill patients with COVID-19: A multicentre observational cohort study. J Infect. 2023; 86(3): 256–308, doi: 10.1016/j.jinf.2022.12.027, indexed in Pubmed: 36596315.

20. Pilgram L, Appel KS, Ruethrich MM, et al. Use and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS): a multicentre cohort study. Infection. 2023; 51(4): 1033–1049, doi: 10.1007/s15010-023-01994-0, indexed in Pubmed: 36763285.

21. Romero I, Cornú E, Pálizas F, et al. [ROX index, high-flow oxygen therapy and COVID-19 pneumonia]. Medicina (B Aires). 2023; 83(3): 411–419, indexed in Pubmed: 37379538.

22. de Carvalho VC, da Silva Guimarães BL, Fujihara MT, et al. Daily ROX index can predict transitioning to mechanical ventilation within the next 24 h in COVID-19 patients on HFNC. Am J Emerg Med. 2023; 73: 160–165, doi: 10.1016/j.ajem.2023.08.045, indexed in Pubmed: 37688983.